Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Argutus Medical’s AKI Test Selected for Innovators Place™

Published: Thursday, October 25, 2012
Last Updated: Thursday, October 25, 2012
Bookmark and Share
Specialists in organ injury present RenaStat at ASN Kidney Week 2012.

Argutus Medical has been chosen as one of ten companies to display their latest product at the Innovators Place™ during the American Society of Nephrology (ASN) Kidney Week 2012.

The scientific exposition, which takes place from the 1st to the 4th of November at the San Diego Convention Center, USA, will bring together more than 13,000 professionals from around the globe to learn the latest scientific and medical advances in the field of kidney function and disease. InnovatorsEKF-Diagnostics.gif Place™ will be located in the Kidney Week exhibit hall (Halls A-B-C) in a dedicated exhibition space that provides the opportunity for scientific networking between medical device industry trendsetters and the nephrology community.

At the Innovators Place™, Argutus Medical, a subsidiary of EKF Diagnostics (AIM listed worldwide manufacturer of point-of-care diagnostic tools, organ injury biomarkers and assays) will showcase its new point-of-care test, the RenaStat. Renastat has been developed to detect the early onset of severe acute kidney injury (AKI) in critical care settings. Argutus’ team of AKI experts will provide attendees with an insight into the RenaStat test, as well as scientific information on the development and use of biomarkers for AKI detection.

RenaStat combines novel microfluidic and magnetic immuno-chromatographic technologies (MICT) to allow accurate detection of alpha and pi glutathione S-Transferase (GSTs) in less than 15 minutes from 100µl of patient urine. This rapid, early assessment of biomarkers enables clinicians to promptly identify and carry out appropriate patient treatment.

"Being selected to showcase at such a high profile meeting as Kidney Week 2012, is a privilege and testament to the hard work that has gone into developing RenaStat through years of research and development. Argutus representatives will be on hand to discuss with our renal medicine colleagues how the application of RenaStat can improve patient diagnosis and treatment" said Joe Keenan, General Manager at Argutus.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

EKF Diagnostics’ Growth Drives New Role Creation
Expanding business welcomes new faces to further strengthen IVD expertise and new product development.
Saturday, July 18, 2015
EKF Diagnostics Collaborates with Joslin Diabetes Center
Supporting the ongoing clinical and commercial development of early Diabetic Kidney Disease biomarkers.
Monday, November 17, 2014
Studies Validate EKF Diagnostics’ Early Stage Test for Progressive DKD
Independent scientific evidence confirms novel sTNFR1/2 biomarkers can accurately predict end-stage renal disease, up to 10 years in advance.
Friday, May 23, 2014
New Clinical Diagnostics Distributor Program Enhances EKF Customer Service
EKF Diagnostics appoints Simona Carnielli as new EMEA Distribution Manager.
Thursday, May 08, 2014
EKF Diagnostics Acquires Separation Technology
Acquisition complements EKF’s existing offering in the hemoglobin testing market place.
Thursday, March 27, 2014
PointMan™ Enriches Low-level DNA Mutations from Whole Blood
Ultra-sensitive PointMan™ enables blood sampling instead of tissue biopsies for cancer patient mutation status assessment.
Wednesday, January 22, 2014
Scientific News
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Magnetic Nanoparticles May Reveal Early Traces Of Cancer
Rice University students’ computer program aids MD Anderson diagnostic initiative .
New Blood Test for The Earlier Diagnosis of Breast Cancer Spread
Researchers at University of Westminster have confirmed that a new blood test can detect if breast cancer has spread to other parts of the body.
Genetic Approach May Lead to New Treatments for Digestive Diseases
Researchers at UMass Medical School have identified a new molecular pathway critical for maintaining the smooth muscle tone that allows the passage of materials through the digestive system.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
World-First Blood Test For Parkinson's
La Trobe University researchers have developed a world-first diagnostic blood test which could change the lives of people with Parkinson's disease.
Parsortix Demonstrates Benefits Over Marker-Based Systems
Research published online in the International Journal of Cancer, shows the ParsortixTM System efficiently captures and harvests intact, viable circulating tumour cells (CTCs), including EpCAM-negative CTCs, to allow for broader downstream CTC analysis.
Hepatitis C Virus Testing Guidelines Miss Too Many Cases
Urban emergency departments a good place to enact universal screening for adults.
NIH Sequences Genome of a Fungus
Researchers at the Institute have sequenced genome of human, mouse and rat Pneumocystis that cause life-threatening Pneumonia in immunosuppressed hosts.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!